Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Organon. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. The pharmaceutical company's shares have seen a decrease of 7.33% over the last month, not keeping up with the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59%. OGN's full-year Z ...